(Journal Article): Remission in models of type 1 diabetes by gene therapy using a single chain insulin-analogue.
 
Lee HC, Kim SJ, Kim KS, Shin HC, Yoon JW (Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, Korea, endohclee(at)yumc.yonsei.ac.kr )
 
IN: Nature 2000; 408(6811):483-488
Impact Factor(s) of Nature: 29.273 (2005), 32.182 (2004), 30.979 (2003), 30.432 (2002), 27.955 (2001)

Fulltext:    HTML  PDF

ABSTRACT: A cure for diabetes has long been sought using several different approaches, including islet transplantation, regeneration of beta cells and insulin gene therapy. However, permanent remission of type 1 diabetes has not yet been satisfactorily achieved. The development of type 1 diabetes results from the almost total destruction of insulin-producing pancreatic beta cells by autoimmune responses specific to beta cells. Standard insulin therapy may not maintain blood glucose concentrations within the relatively narrow range that occurs in the presence of normal pancreatic beta cells. We used a recombinant adeno-associated virus (rAAV) that expresses a single-chain insulin analogue (SIA), which possesses biologically active insulin activity without enzymatic conversion, under the control of hepatocyte-specific L-type pyruvate kinase (LPK) promoter, which regulates SIA expression in response to blood glucose levels. Here we show that SIA produced from the gene construct rAAV-LPK-SIA caused remission of diabetes in streptozotocin-induced diabetic rats and autoimmune diabetic mice for a prolonged time without any apparent side effects. This new SIA gene therapy may have potential therapeutic value for the cure of autoimmune diabetes in humans.

TYPE OF PUBLICATION: Original article

Articles citing this article:

• Assady S, Maor G, Amit M, Itskovitz-Eldor J, Skorecki KL, Tzukerman M. Insulin production by human embryonic stem cells. Diabetes 2001. 50: 1691-1697.
  » Diabetes OD » Regeneration of Islets » Stem Cells » Embryonic Stem Cells » Journal Article